Bioseeker, Feb 2011
and the accumulated number of ceased drugs over the last years amount to another 74 (71) drugs. OvarianCancerDrugPipelineUpdate lists all drugs and gives you a progress analysis on each one of them. Identified
Life Science Analytics, March 2011, Pages: 656
OvarianCancer Therapy Area Pipeline Report contains detailed information on the ovariancancerdrugpipeline. This report provides insight into the pipeline status of ovariancancerdrugs
GlobalData, Dec 2010, Pages: 49
and major milestones.
- Recent updates of AGO OvarianCancer Study Group’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug
Global Markets Direct, March 2011, Pages: 48
- Identify new drug targets and therapeutic classes in AGO OvarianCancer Study Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing
Global Markets Direct, Dec 2010, Pages: 49
- Identify new drug targets and therapeutic classes in AGO OvarianCancer Study Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing
Global Markets Direct, Jan 2011, Pages: 286
OvarianCancer - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'OvarianCancer - Pipeline Review, Q1 2011', provides an overview of the OvarianCancer therapeutic pipeline. This report
Bioseeker, Dec 2007, Pages: 430
by Molecular Function Classes of Targets 3(3)
Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
GBI Research, Nov 2010, Pages: 85
Market and Application of Oral Drug Delivery Systems
9.2.3 Analysis of the Global Anti-Obesity Therapeutics Market and Applications of Oral Drug Delivery Systems
9.3 Oncology
9.3.1 Analysis of the Global OvarianCancer
Global Markets Direct, Dec 2010, Pages: 32
and major milestones.
- Recent updates of the James Graham Brown Cancer Center’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products
Global Markets Direct, Dec 2010, Pages: 33
and major milestones.
- Recent updates of the Ottawa Regional Cancer Foundation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products
Datamonitor, April 2010, Pages: 243
of the current small molecule targeted cancer therapies pipeline by developmental phase, drug target and company
-Insight and analysis of market potential including commercial opportunity and discussion of unmet
Global Markets Direct, Jan 2012, Pages: 145
of Action
R&D Progress
Peritoneal Cancer Therapeutics – Drug Profile Updates
Peritoneal Cancer Therapeutics – Discontinued Products
Peritoneal Cancer Therapeutics - Dormant Products
Peritoneal
Global Markets Direct, Jan 2012, Pages: 150
pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also
Global Markets Direct, Jan 2011, Pages: 78
pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also
Global Markets Direct, Nov 2011, Pages: 66
: Telik Reports Results Of TELCYTA Assist-3 Trial
May 03, 2006: Telik Announces Initiation Of New Telcyta Phase III Clinical Trial And Updates Status Of Ongoing Phase III OvarianCancer Clinical Trials
Global Markets Direct, July 2011, Pages: 324
– Drug Profile UpdatesOvarianCancer Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Ovarian
GlobalData, Nov 2010, Pages: 36
Receives FDA Approval To Continue Phase IIb Superficial Bladder Cancer Clinical Trial
Aug 24, 2009: BioCancell Receives Orphan Drug Status From FDA For OvarianCancerDrug
Jan 13, 2009: Bio
Global Markets Direct, Nov 2010, Pages: 36
Cancell Receives Orphan Drug Status From FDA For OvarianCancerDrug
Jan 13, 2009: BioCancell Receives FDA Approval For Pancreatic & OvarianCancer Trials
Jan 13, 2009: BioCancell Receives FDA Approval
Global Markets Direct, Jan 2011, Pages: 66
Peritoneal Cancer - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Peritoneal Cancer - Pipeline Review, Q1 2011', provides an overview of the Peritoneal Cancer therapeutic pipeline
